Program
PI3K/mTOR Kinase Inhibitor WXFL10030390
Also written as “WX390”, “WX390 1.1mg + Toripalimab 240mg” and “WXFL10030390”.
Its studies are mostly in Uterine Cervical Neoplasms, led by Shanghai Jiatan Pharmatech.
Drug pagePI3K/mTOR Kinase Inhibitor WXFL10030390: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Jan 20, 20266 company-led studies, 4 open or runningNext primary completion: Sep 30, 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Jiatan Pharmatech | 64 open or running | phase 3since Jan 20, 2026 | Oct 21, 2018 | Sep 30, 2029phase 3 · NCT07392060 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 21, 2018First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesFirst studyNCT03730142 · 82 enrolled · China
- Oct 30, 20233 phase 2 studiesNCT06124963, NCT06117566, NCT06117540
- Nov 3, 2023Phase 2 study in PIK3CA Mutation-Related TumorsNCT06132932 · 38 enrolled · China
- Jan 20, 2026Phase 3 study in Cervical Cancer MetastaticPhase 3 reachedNCT07392060 · 440 planned
Ahead
- Sep 30, 2029Primary completion: phase 3 study in Cervical Cancer MetastaticNCT07392060
TargetBeta
MTOR →read by rule
“An orally bioavailable, small molecule inhibitor of certain phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, ”NCIt, by rule
Other programs on MTOR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Sirolimus | Pfizer | phase 4 | 66 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| sapanisertibrule | Takeda | phase 2 | 14 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07392060Cervical Cancer Metastatic | 3 | Not yet recruiting | Sep 30, 2029 | 440 |
| NCT06132932PIK3CA Mutation-Related Tumors · China | 2 | Completed | Jan 3, 2023 | 38 |
| NCT06124963Gastric Type Adenocarcinoma (GAS) With STK11 Mutation · China | 2 | Recruiting | Dec 12, 2025 | 20 |
| NCT06117566Solid Tumor · China | 2 | Recruiting | Nov 9, 2025 | 100 |
| NCT06117540Solid Tumor · China | 2 | Recruiting | Jun 12, 2025 | 70 |
| NCT03730142Hereditary Sensory and Autonomic Neuropathies · China | 1 | Completed | Jul 25, 2020 | 82 |
How it is read
Names in the registry
- “WX390”, 4 entries
- “WX390 1.1mg + Toripalimab 240mg”, 1 entry
- “WXFL10030390”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.